Roche, Tesaro decline to comment on potential bid

Roche (SIX:ROG; OTCQX:RHHBY) and Tesaro Inc. (NASDAQ:TSRO) declined to comment on an Intereconomía report that said Roche is working with Citibank on a bid to acquire Tesaro. Intereconomía cited sources familiar with the matter.

This month, Tesaro and the Genentech Inc. unit of Roche partnered to test Tesaro's PARP inhibitor Zejula niraparib in combination with Tecentriq atezolizumab and Cotellic cobimetinib to treat platinum-sensitive ovarian cancer. In February, the companies partnered to conduct a Phase Ib/II trial of Zejula in combination with Tecentriq to treat metastatic bladder cancer. ...